News
ANR à fin septembre 2011 : 7,74 euros par action / Plus-values de cession : 4,2 millions deuros
Paris, le 3 novembre 2011 : Turenne Investissement affiche de très solides performances financières à fin septembre 2011 avec une nouvelle progression de son actif net réévalué
Chiffre daffaires du 3ème trimestre 2011
Chiffre d’affaires - M€ – IFRS
2011
2010
Variation
1er trimestre
6,42
6,54
-1,8 %
2ème trimestre
7,26
8,63
-15,9 %
OVERLAP Groupe annonce la disponibilité immédiate de son offre de Cloud computing - Avec cette solution baptisée "Infrastructure à la demande", OVERLAP Groupe accélère son évolution vers les services à forte valeur ajoutée
OVERLAP Groupe, leader français des infrastructures informatiques haut de gamme, dispose d’offres de services managés et d’infogérance d’infrastructures (serveurs,
ARCHOS, PARTENAIRE OFFICIEL DES SOMMETS G20 et B20
ARCHOS est partenaire officiel des Sommets G20 et B20
Cannes – 2, 3 et 4 novembre 2011
Sous la Présidence française du G20, ARCHOS a été choisi comme partenaire
Résultats semestriels en nette amélioration - Forte hausse de la valeur de la production agricole attendue en 2011 à 32 M EUR soit +60%
Paris – le 2 novembre 2011 - AgroGeneration, groupe agricole spécialisé dans la production de céréales et d’oléagineux, annonce aujourd’hui
Pharnext 2019 Universal Registration Document Approved by AMF
Pharnext 2019 Universal Registration Document Approved by AMF
DECATHLON and ROCTOOL sign their first development and innovation agreement
DECATHLON and ROCTOOL sign their first development and innovation agreement
Pharnext to Host Research and Development Event Today
Pharnext to Host Research and Development Event Today
Edison Investment Research Limited: Edison issues initiation on Pharnext (ALPHA)
Edison Investment Research Limited: Edison issues initiation on Pharnext (ALPHA)
Pharnext to Host Research and Development Day on October 13, 2020
Pharnext to Host Research and Development Day on October 13, 2020
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Edison Investment Research Limited: Edison issues outlook on Riber (RIB)
Edison Investment Research Limited: Edison issues outlook on Riber (RIB)
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Reports Financial Results for Year-End 2019
Pharnext Reports Financial Results for Year-End 2019
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer
ROCTOOL: Roctool measures the advantages of its technology with new plastics
ROCTOOL: Roctool measures the advantages of its technology with new plastics
Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its PleotherapyTM Platform
Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its PleotherapyTM Platform
Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency
Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency